Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Go back to Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.93 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.93 | 52 Week High | $118.49 | |||
| Open | $126.93 | 52 Week Low | $55.00 | |||
| Day High | $126.93 | P/E | N/A | |||
| Day Low | $126.93 | EPS | $-0.56 | |||
| Volume | 6,126 | |||||
